CymitQuimica logo

CAS 845533-86-0

:

Bedaquiline fumarate

Description:
Bedaquiline fumarate is a novel anti-tuberculosis medication primarily used in the treatment of multidrug-resistant tuberculosis (MDR-TB). It is a diarylquinoline compound that selectively inhibits the ATP synthase enzyme in Mycobacterium tuberculosis, disrupting the bacterium's energy production and leading to its death. The fumarate salt form enhances its solubility and stability. Bedaquiline is characterized by its long half-life, allowing for once-daily dosing, which improves patient adherence to treatment regimens. Common side effects may include nausea, headache, and potential cardiovascular effects, such as QT interval prolongation, necessitating monitoring during therapy. It is typically used in combination with other anti-TB agents to prevent the development of resistance. Due to its specific mechanism of action and the emergence of drug-resistant strains of tuberculosis, Bedaquiline represents a significant advancement in the fight against this global health challenge. Its approval by regulatory agencies has provided a new therapeutic option for patients with limited treatment alternatives.
Formula:C32H31BrN2O2·C4H4O4
SMILES:[C@]([C@@H](C=1C(OC)=NC2=C(C1)C=C(Br)C=C2)C3=CC=CC=C3)(CCN(C)C)(O)C=4C5=C(C=CC4)C=CC=C5.C(=C/C(O)=O)\C(O)=O
Synonyms:
  • (1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-naphthalen-1-yl-1-phenylbutan-2-ol,(E)-but-2-enedioic acid
  • (4R,12aS)-7-(benzyloxy)-9-bromo-4-methyl-3,4-dihydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-6,8(12H,12aH)-dione
  • 3-Quinolineethanol, 6-bromo-α-[2-(dimethylamino)ethyl]-2-methoxy-α-1-naphthalenyl-β-phenyl-, (αS,βR)-, (2E)-2-butenedioate (1:1) (salt)
  • Bedaquiline fumarate
  • R 403323
  • Sirturo
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 6 products.